Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $100.9952W HIGH $198.87
Volume
4.65 M
Value Traded
126.02 M
Short % Float
11.92%
Days to Cover
4.9
-1.79%Week
-0.16%1 Month
+20.32%3 Month
+49.68%6 Month
-36.81%5 Year
+922.76%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
9.99 B
EPS (TTM)
0.65
P/E Ratio
270.43
Ent. Value
9.68 B
Total Shares
56.44 M
Float Shares
59.96 M
Insiders
5.56%
Institutions
111.61%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
RGEN Catalyst Timeline
Dated clinical, regulatory and corporate events for Repligen Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Repligen Corporation
476Total events
0Upcoming
115Tier-1 (high impact)
2010 to 2026Coverage
Event history 50
●Quarterly UpdateCorporate
Repligen reports Q3 2026 financial results with revenue of $209 million
●Manufacturing MilestoneCMC / Inspection
Repligen opens new Training & Innovation Center (RTIC) in Seoul, South Korea
●Manufacturing MilestoneCMC / Inspection
Opened new Repligen Training & Innovation Center in Breda, Netherlands
◆Timing GuidancePresentation
Additional detail on transaction's expected impact on 2026 financial outlook to be provided on Q3 2026 earnings call
◆Oral PresentationPresentation
Repligen to present at William Blair 46th Annual Growth Stock Conference
◆Oral PresentationPresentation
Repligen to present at Bank of America Securities 2026 Global Healthcare Conference
▲Manufacturing MilestoneCMC / Inspection
Grand opening of Repligen Training & Innovation Center in Breda, Netherlands
◆Management ChangeCorporate
Tony Hunt retires as Executive Chair and Board member, effective March 13, 2026
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference presentation
◆Oral PresentationPresentation
Repligen Corporation presentation at J.P. Morgan 2026 Healthcare Conference
◆Oral PresentationPresentation
Repligen to present at five upcoming investor conferences in November 2025
▲Partnership / LicenseCorporate
Strategic partnership with Novasign for digital twin integration
▲Partnership / LicenseCorporate
Strategic partnership with Novasign to integrate modeling workflow into filtration systems
◆Oral PresentationPresentation
Repligen to present company overview at William Blair Growth Conference
▲Partnership / LicenseCorporate
Repligen purchases bioprocessing analytics portfolio from 908 Devices
◆Oral PresentationPresentation
Repligen Corporation presentation at 43rd Annual J.P. Morgan Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How RGEN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2012-06-22 | RG1068 (synthetic human secretin) | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
5
Drugs Scored
rNPV / MCap
Top Drug
Top 75%
Small Cap(rank 493 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every RGEN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| RG3039 | spinal muscular atrophy (SMA) | Phase 1 | 2012-04-25 | 90% inhibition of the target enzyme; well tolerated at all doses administered; no serious adverse events reportedRead More | Repligen Reports Positive Results From Phase 1 Clinical Trial for Spinal Muscular Atrophy (SMA)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Loeillot OlivierDirector, Officer (Chief Executive Officer) | Sell | -1,333 45,788 held | $178.75 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RGEN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 1.4 % | 169.27 M | 1.24 M | 2.87% ( 34.64 K) |
RGEN Institutional Ownership Trends
RGEN Short Interest
Shares sold short, counted twice a month.
11.92%
Short % of Float
of tradable shares sold short
7.1M
Shares Sold Short
-5.8% vs prior count
4.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.5M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RGEN ranks across every disease it competes in
Competitive Position is a premium feature
See how RGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRGEN News
RGEN▼ -6.2%on this news
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
Repligen Corporation announced a $1 billion transaction involving the issuance of 0.25% Convertible Senior Notes due 2031. The deal includes exchanging existing notes and raising cash, with plans to use proceeds for share repurchases and general corporate purposes. The CFO highlighted benefits such as reduced interest expenses and enhanced financial flexibility.
Read more →RGEN▼ -6.2%today
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen Corporation reported third quarter 2026 revenue of $209 million, marking an 11% increase year-over-year. The company completed the acquisition of BioLife Solutions, enhancing its position in the cell therapy market. Repligen raised its full-year revenue guidance to between $844 million and $852 million, reflecting strong demand and operational synergies.
Read more →RGENRepligen to Report Third Quarter 2026 Financial Results
Repligen Corporation has announced that it will report its third quarter 2026 financial results on October 27, 2026. A press release will be issued before the market opens, followed by a conference call at 8:00 a.m. ET to discuss the results and business updates. The call will be accessible to both domestic and international callers.
Read more →RGEN▼ -7.7%on this news
Repligen Completes Acquisition of BioLife Solutions
Repligen Corporation has completed its acquisition of BioLife Solutions, enhancing its position in the cell therapy market. This acquisition introduces a high-margin consumables business and strengthens Repligen's product portfolio. The integration plan aims to leverage both companies' strengths to better serve customers in the cell therapy workflow. Financial details include cash and stock compensation for BioLife stockholders.
Read more →RGENRepligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference
Repligen Corporation will participate in the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. CEO Olivier Loeillot and CFO Jason Garland will engage in an analyst-led discussion. A live webcast will be available for those unable to attend in person, highlighting the company's focus on bioprocessing technologies.
Read more →RGEN▲ +10.9%on this news
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen Corporation reported a strong second quarter for 2026, with revenues of $204 million, reflecting a 12% increase year-over-year. The company raised its full-year guidance for organic revenue growth and adjusted EPS, driven by robust market performance and the announcement of its acquisition of BioLife Solutions. Despite a decrease in GAAP EPS, the overall financial outlook remains positive.
Read more →RGENRepligen to Report Second Quarter 2026 Financial Results
Repligen Corporation announced it will report its second quarter 2026 financial results on July 28, 2026. A press release will precede the market opening, followed by a conference call at 8:00 a.m. ET to discuss the results. The call will be accessible for both domestic and international callers, and a webcast will be available on the company's website.
Read more →RGENRepligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
Repligen Corporation will present at the William Blair 46th Annual Growth Stock Conference on June 3rd. CEO Olivier Loeillot will provide a company overview during the event. A live webcast will be available for those unable to attend in person. Repligen focuses on bioprocessing technologies for biopharmaceutical manufacturing.
Read more →RGENRepligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
Repligen Corporation has published its 2025 Corporate Sustainability Report, highlighting its commitment to sustainability across six key impact areas. The report includes disclosures aligned with the UN Sustainable Development Goals and various reporting frameworks. Key achievements include maintaining renewable energy in operations and adopting new sustainability policies. The company emphasizes transparency and continuous improvement in its sustainability efforts.
Read more →RGENRepligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference
Repligen Corporation will present at the Bank of America Securities 2026 Global Healthcare Conference from May 12-14 in Las Vegas. CFO Jason Garland will lead an analyst discussion on May 12 at 10:00am PT. A live webcast of the presentation will be available on Repligen's Investor Relations website.
Read more →RGEN▲ +6.3%on this newsshared move
Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Repligen Corporation reported a strong first quarter for 2026, with revenues reaching $194 million, marking a 15% increase year-over-year. The company also saw significant growth in earnings per share, with a 50% rise in GAAP EPS. Repligen reiterated its guidance for organic revenue growth and adjusted EPS for the full year, reflecting confidence in its strategic initiatives and market position.
Read more →RGEN▼ -6.3%on this news
Repligen to Report First Quarter 2026 Financial Results
Repligen Corporation will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The company plans to issue a press release before the market opens that day. A conference call will follow at 8:00 a.m. ET to discuss business updates. This call covers the three-month period ended March 31, 2026.
Read more →RGENRepligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network
Repligen Corporation has inaugurated its new Training & Innovation Center in Breda, Netherlands, aimed at enhancing customer support through hands-on training and product demonstrations. This facility is the third of its kind globally, joining locations in Waltham and Tokyo. The opening reflects Repligen's commitment to investing in customer proximity and expanding its bioprocessing technology offerings.
Read more →RGENRepligen Corporation to Present at Upcoming March Conferences
Repligen Corporation will participate in three investor conferences in March 2026, including the Leerink Global Healthcare Conference and the Barclays Annual Global Healthcare Conference. CFO Jason Garland will lead discussions at both events, while CEO Olivier Loeillot will speak at the KeyBanc Virtual Healthcare Forum. Webcasts of the presentations will be available for investors.
Read more →RGENRepligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Repligen Corporation reported strong financial results for Q4 2025, achieving 14% organic growth, primarily driven by its Analytics and Proteins segments. The company exceeded its revenue guidance for the year and anticipates continued growth in 2026, despite facing a potential headwind from gene therapy. Repligen's CEO expressed optimism about their product portfolio and operational strategy moving forward.
Read more →RGENRepligen to Report Fourth Quarter and Full Year 2025 Financial Results
Repligen Corporation will announce its fourth quarter and full year 2025 financial results on February 24, 2026. A press release will precede the market opening, followed by a conference call at 8:30 a.m. ET to discuss the results. The call will be accessible to both domestic and international callers, with a webcast available on the company's website.
Read more →RGENREPLIGEN Executive chair tony hunt to retire
Repligen Corporation has announced the retirement of Executive Chair Tony Hunt, effective March 13, 2026, with Dr. Martin D. Madaus being elected as the new Chair of the Board. Repligen's President and CEO, Olivier Loeillot, praised Hunt's ten-year tenure for expanding the company's innovative product portfolio. Madaus, who has extensive experience in the life sciences and previously led Millipore Corporation, expressed honor in his new role and commitment to guiding the company forward. Hunt will remain as an advisor until March 2027 to ensure a seamless transition.
Read more →RGENRepligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
Repligen Corporation elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. Tony Hunt is retiring from his role as Executive Chair and Board member on the same date. Hunt will continue serving as an advisor to the company through March 2027. Madaus has served as a director since February 2023.
Read more →RGENRepligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
Repligen Corporation will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco. The event runs from January 12 to 15. CEO Olivier Loeillot will deliver an overview of the company on Tuesday, January 13 at 2:15 p.m. PT. A live webcast will be available on the investor relations website for replay after the presentation.
Read more →RGENRepligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows
Repligen Corporation announced the launch of three new chromatography resins designed for gene therapy workflows. The products include AVIPure HiPer AAV9 and AAV8 affinity resins alongside a HiPer QA anion exchange resin. These items utilize Tantti DuloCore base bead technology to support viral vector processing. The company plans additional resin launches in 2026 to expand its bioprocessing portfolio.
Read more →About Repligen Corporation
Headquarters41 SEYON STREET, WALTHAM, MA, 02453
BIOPHARMAWATCH ELITE PLUS
Trade the next RGEN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime